PRAVACHOL TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PRAVASTATIN SODIUM

제공처:

BRISTOL-MYERS SQUIBB CANADA

ATC 코드:

C10AA03

INN (International Name):

PRAVASTATIN

복용량:

20MG

약제 형태:

TABLET

구성:

PRAVASTATIN SODIUM 20MG

관리 경로:

ORAL

패키지 단위:

90

처방전 유형:

Prescription

치료 영역:

HMG-COA REDUCTASE INHIBITORS

제품 요약:

Active ingredient group (AIG) number: 0122563002; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2020-11-27

제품 특성 요약

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PRAVACHOL
®
pravastatin sodium
20 and 40 mg
Lipid Metabolism Regulator
Bristol-Myers Squibb Canada
Montréal, Canada
®
Registered trademark
of Bristol-Myers Squibb Company
used under licence by Bristol-Myers Squibb Canada
Date of Preparation:
August 16, 1990
Date of Revision:
March 4, 2020
Submission Control No: 234107
_ _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PRODUCT MONOGRAPH
.........................................................................................................1
TABLE OF CONTENTS
.................................................................................................................2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
5
WARNINGS AND PRECAUTIONS
.....................................................................................
5
ADVERSE REACTIONS
.....................................................................................................
11
DRUG INTERACTIONS
.....................................................................................................
16
DOSAGE AND ADMINISTRATION
.................................................................................
18
OVERDOSAGE
...................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 19
STORAGE AND STABILITY
.............................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 21
PART II